Assessment of low-dose weight-loss drug use for longevity in lean individuals, reviewing biological mechanisms, evidence, and potential harms.
Key Takeaways
- GLP-1 drugs produced up to 24% mean weight loss in a 2023 phase 2 trial
- Semaglutide users showed a 20% reduction in major cardiovascular events
- There are no long-term clinical longevity studies in healthy normal-weight GLP-1 users